Study guide

21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy

UEMS European Board of Dermatovenereology Diploma Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Eligibility & Examination Regulations

1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition

2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology

2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns

3 Chapter 3: Dermatopathology & Diagnostic Procedures

3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy

4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology

4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance

5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease

5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders

6 Chapter 6: Hair, Nails & Pigmentary Disorders

6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation

7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease

7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses

8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease

8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease

9 Chapter 9: Autoimmune Bullous Diseases

9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis

10 Chapter 10: Eczematous Disorders, Urticaria & Allergology

10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy

11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis

11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses

12 Chapter 12: Paediatric & Genetic Dermatology

12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa

13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections

13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections

14 Chapter 14: Viral & Fungal Cutaneous Infections

14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses

15 Chapter 15: Sexually Transmitted Infections & Genital Infections

15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis

16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine

16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems

17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours

17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases

18 Chapter 18: Melanocytic Naevi & Melanoma

18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma

19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas

19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas

20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing

20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy

21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures

21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy

22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision

22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review

21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy

Key Takeaways Explain This Topic AI

Botulinum toxin type A cleaves SNAP-25 and blocks acetylcholine release, with an effect that starts in about 2 to 3 days, peaks at about 2 weeks, and lasts about 3 to 4 months in muscle.

Eyelid ptosis after glabellar botulinum toxin results from spread to the levator palpebrae superioris and can be improved with apraclonidine eye drops while it wears off.

Suspected vascular occlusion after hyaluronic acid filler needs immediate injection of high-dose hyaluronidase, and any visual symptoms need emergency ophthalmology review.

Phenol (deep) chemical peels can cause cardiac arrhythmias, so they require cardiac monitoring, intravenous hydration, and treatment in stages.

Daylight photodynamic therapy with a photosensitiser such as methyl aminolevulinate is an effective, less painful option for grade I to II actinic keratoses on the face and scalp.

Last updated: September 2026

21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy

Lasers and electrosurgery are covered in the cryosurgery, electrosurgery, and laser section. This section focuses on injectables, peels, other aesthetic devices, photodynamic therapy (PDT), and radiotherapy.

Patient Selection and Regulation

Assess the patient's expectations and screen for body dysmorphic disorder , in which cosmetic procedures should generally be avoided (see the psychodermatology section).

Record medical history, drugs (anticoagulants, isotretinoin), previous procedures and fillers, and keep standard photographs. Obtain written informed consent that covers alternatives and risks.

In the EU, products without a medical purpose, such as dermal fillers and many energy-based aesthetic devices , are regulated under the Medical Device Regulation (Annex XVI) . National rules differ on who may inject.

Botulinum Toxin Type A

Mechanism: the light chain cleaves SNAP-25 , a SNARE protein, and blocks acetylcholine release at the neuromuscular junction and at sweat glands.

Time course: onset about 2–3 days , peak about 2 weeks , duration about 3–4 months in muscle (longer for sweating).

Products: onabotulinumtoxinA, abobotulinumtoxinA, and incobotulinumtoxinA (free of complexing proteins). Units are not interchangeable between products.

Common indications: glabellar lines (corrugator and procerus), lateral canthal lines (orbicularis oculi), forehead lines (frontalis), and primary hyperhidrosis.

Complication Cause and Management

Eyelid ptosis Spread to the levator palpebrae superioris after glabellar injection; apraclonidine eye drops stimulate Müller muscle while it wears off

  • Brow ptosis Injecting the frontalis too low or too heavily
  • Asymmetry, "Spock brow" Uneven injection; small corrective doses
  • Bruising, headache Common, self-limiting
  • Distant spread Rare; dysphagia or weakness

Contraindications: pregnancy and breastfeeding, neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome), infection at the site, and caution with aminoglycosides. Repeated high doses can induce neutralising antibodies.

Dermal Fillers

  • Filler Features
  • Hyaluronic acid (HA) Most widely used; cross-linked to last months; reversible with hyaluronidase
  • Calcium hydroxylapatite Volumising and collagen-stimulating; not reversible
  • Poly-L-lactic acid "Biostimulator" that produces gradual collagen formation over several sessions
  • Permanent fillers (silicone, polymethylmethacrylate) Risk of late granulomas and migration; generally avoided
  • Complications

Early: swelling, bruising, lumps, infection, hypersensitivity, and the Tyndall effect (blue-grey discolouration from HA placed too superficially, treated with hyaluronidase).

Vascular occlusion (emergency): filler injected into or compressing an artery causes immediate pain and blanching , then a reticulate livedo pattern , dusky discolouration, and necrosis. Stop injecting, give high-dose hyaluronidase (repeated until reperfusion) for HA fillers, apply warm compresses and massage, and consider aspirin.

Blindness: retrograde embolism into the ophthalmic artery causes sudden visual loss, pain, and ptosis. It is most linked to the glabella, nose, nasolabial fold, and forehead . It needs emergency ophthalmology review. The outcome is often poor, so prevention (anatomy, aspiration, slow low-pressure injection, cannulas in danger zones) is vital.

Late: inflammatory or biofilm-related nodules, delayed-onset nodules after infections or vaccination, and foreign-body granulomas.

Chemical Peels

Depth Agents Points

Superficial (epidermis) Glycolic acid, salicylic acid, Jessner solution, low-strength trichloroacetic acid (TCA) Acne, melasma, photoageing; little downtime

Medium (papillary dermis) TCA about 35%, often after Jessner or glycolic priming Actinic damage, fine wrinkles; herpes simplex prophylaxis

Deep (reticular dermis) Phenol (Baker-Gordon formula) Deep wrinkles; cardiac arrhythmias , so needs cardiac monitoring, IV hydration, and staged application; also kidney and liver toxicity

Complications: post-inflammatory hyperpigmentation (especially in darker skin types), infection (including herpes simplex), scarring, and lines of demarcation. Avoid medium and deep peels during or shortly after isotretinoin , with active herpes simplex, and in pregnancy.

Other Aesthetic Devices and Procedures

Intense pulsed light (IPL): broadband light (about 500–1,200 nm) with filters for vascular lesions, lentigines, and hair removal.

Laser hair removal: alexandrite (755 nm), diode (about 810 nm), and Nd:YAG (1,064 nm) for darker skin types . Paradoxical hypertrichosis is a recognised side effect.

Tattoo removal: Q-switched and picosecond lasers. White, flesh-coloured, and some red inks containing iron or titanium oxide can darken paradoxically . Red tattoo ink is a common cause of allergic reactions.

Radiofrequency, microneedling, and high-intensity focused ultrasound: skin tightening and scar improvement.

Cryolipolysis: non-invasive fat reduction; paradoxical adipose hyperplasia is a rare complication.

Sclerotherapy of leg telangiectasia and reticular veins: see the phlebology section.

Photodynamic Therapy (PDT)

Principle: a topical precursor, 5-aminolevulinic acid (ALA) or methyl aminolevulinate (MAL) , is converted in abnormal cells to protoporphyrin IX . Light activates it to form reactive oxygen species that destroy the cells.

Light sources: red light (about 630–635 nm) for conventional PDT, blue light, or daylight .

Indications: actinic keratoses and field cancerisation, Bowen disease , and superficial (and thin nodular) basal cell carcinoma . It is not used for invasive squamous cell carcinoma or melanoma.

Daylight PDT: European consensus supports it for grade I–II actinic keratoses on the face and scalp . It is as effective as conventional PDT and much less painful .

Side effects: pain during illumination (conventional PDT), erythema, oedema, crusting, and temporary pigment change. Cosmetic results are usually very good.

Dermatological Radiotherapy

Types: superficial X-rays (including very low-energy Grenz rays), electron beam, and brachytherapy.

Indications:

Basal cell and squamous cell carcinoma in older patients, or where surgery would be difficult (eyelid, nose, lip, ear).

Adjuvant radiotherapy for high-risk cSCC (for example positive margins or major nerve involvement) and for Merkel cell carcinoma.

Lentigo maligna in selected patients unsuitable for surgery.

Cutaneous lymphomas (localised radiotherapy, total skin electron beam therapy for mycosis fungoides) and Kaposi sarcoma .

Keloids , as adjuvant treatment soon after excision.

Cautions and contraindications: Gorlin syndrome and xeroderma pigmentosum (radiation induces new tumours), younger patients (late skin changes and second cancers appear over decades), previously irradiated sites, poorly healing areas such as the lower leg, and some connective tissue diseases (systemic sclerosis).

Late effects: atrophy, telangiectasia, pigment change, fibrosis, alopecia, and radiation-induced cancers (see the physical injury section).